No Data
No Data
No Data
No Data
No Data
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of PAS-004
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern Europ
GlobeNewswireFeb 13 07:59 ET
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
BenzingaJan 2 09:00 ET
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout
GlobeNewswireJan 2 08:35 ET
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA) today announced that its meeting of stockholders, which had been
GlobeNewswireDec 28, 2023 17:00 ET
Pasithea Therapeutics Announces Results From 2023 Annual Meeting
SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA), today announced that it held its annual meeting of stockholders (the
GlobeNewswireDec 19, 2023 17:19 ET
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 From NRAS Mutation Cancer Xenograft Models
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced positive preclinical results from two in vivo studies evaluating the anti-tumor efficacy of PAS-004 in NRAS mutation cancer xenograft models.
GlobeNewswireDec 11, 2023 08:01 ET
No Data
No Data